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SUMMARY 
 
Meta-analysis provides a family of statistical techniques for combining the results of similar studies. 
This paper examines the meta-analysis of clinical data in economic studies, and points to the issues 
and considerations that must be addressed when designing and conducting a meta-analysis of clinical 
data for use in an economic evaluation. We investigate whether the standard approaches employed in 
the meta-analysis of clinical data are satisfactory to meet the demands of economic evaluation, and 
assess the meta-analyses contained in a sample of economic evaluations identified from the NHS 
Economic Evaluation Database. Finally, we provide guidance on the appropriate use of meta-analysis 
for economic evaluations.  
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1.  INTRODUCTION 
 
In recent years, economic evaluation has become an increasingly important decision-making tool to 
help address resource allocation issues. Economic evaluations of health care interventions are 
frequently based upon prospective randomised clinical trials (RCTs) (Adams et al., 1992), but the 
integration of economic evaluations and clinical trials has not been without difficulties (Drummond & 
Davies, 1991). Furthermore, the prospective design may not be feasible, appropriate or sufficient for 
the needs of economic analysis in certain situations. As a consequence, a good proportion of 
economic evaluations are to varying extents reliant upon models, which synthesise data from different 
research studies, expert opinion, existing literature and databases. Some researchers have argued that 
modelling is an unavoidable fact of life (Buxton et al., 1997), but others have argued that analysts 
should be inherently aware of the limitations (Sheldon, 1996).  
 
Meta-analysis provides a family of statistical techniques for combining the results of similar studies. 
This paper examines the meta-analysis of clinical data in economic studies, and points to the issues 
and considerations that must be addressed when designing and conducting such a meta-analysis of 
clinical data for use in an economic evaluation. An implicit question is whether the standard 
approaches employed in the meta-analysis of clinical data are satisfactory to meet the demands of 
economic evaluation. 
 
Although this paper focuses on meta-analyses that evaluate the effectiveness of interventions across 
several clinical studies, it is noted that meta-analysis may also be used for components of economic 
evaluation that are not measurable in the clinical studies, e.g. resource use and quality of life 
measurements. 
 
2.  ECONOMIC EVALUATION AND THE ROLE OF META-ANALYSIS 
 
Conceptually, economic evaluation is relatively straightforward and the methods of economic 
evaluation have been described extensively elsewhere (Drummond et al. 1997). However, the value 
and validity of the results of economic evaluation are critically dependent upon the health outcomes 
data available. In cost-effectiveness analysis, the estimates of effectiveness are often incorporated into 
the denominator. 
 
The purpose of meta-analysis is to answer item 3 of the methodological checklist for economic 
evaluations (Drummond et al., 1997): ‘Was the effectiveness of the programmes or services 
established ?’ and to address adequately sub-item 3.2: ‘Was effectiveness established through an 
overview of clinical studies ?’    The Use of Meta-Analysis in Economic Evaluation  2 
 Box 1: Checklist for Assessing Economic Evaluations 
1.   Was a well-defined question posed in answerable form ? 
2.   Was a comprehensive description of the competing alternatives given ? 
3.   Was the effectiveness of the programmes or services established ? 
  3.1 Was this done through a randomized controlled trial? If so, did the protocol  
        reflect what would happen in regular practice ? 
  3.2 Was effectiveness established through an overview of clinical studies ? 
  3.3 Were observational data or assumptions used to establish effectiveness? 
        If so, what are the potential biases in results ? 
4.   Were all the important and relevant costs and consequences for each alternative 
       identified ? 
5.   Were costs and consequences measured accurately in appropriate physical units? 
6.   Were costs and consequences valued credibly ? 
7.   Were costs and consequences adjusted for differential timing ? 
8.   Was an incremental analysis of costs and consequences of alternatives performed? 
9.   Was allowance made for uncertainty in the estimates of costs and consequences? 
10. Did the presentation and discussion of study results include all issues of concern to users ? 
       Drummond  et  al.,  1997 
 
As the amount of clinical research available is daunting and unmanageable,  systematic reviews are 
needed to efficiently integrate valid information and provide a basis for rational decision-making 
(Mulrow, 1994). Unlike traditional literature reviews which have been criticised for being subjective 
(Chalmers, 1991), systematic reviews are more objective and reliable by systematically locating, 
appraising and synthesising evidence from scientific studies (Deeks et al 1996). The results of primary 
studies may be quantitatively combined or narratively summarised in a systematic review. A meta-
analysis is a systematic review in which statistical method is used to combine results of primary 
studies quantitatively (Der Simonian and Laird, 1986). Figure 1 shows the relationship between meta-
analysis and systematic review. It should be stressed that some published meta-analyses may not be 
systematic in their search for literature and assessment of quality of included studies. 
 
By combining many small studies in a meta-analysis, small but important effects that otherwise might 
not have been detected can be picked up and reduce the possibility of a type II error (where there 
seems to be no statistically significant treatment effect, when in reality such an effect exists). The 
enlarged sample size also generates more precise estimates and facilitates subgroup analysis, revealing 
patterns of correlation or variation of treatment effect across studies. As an element of meta-analysis 
involves the critical assessment of primary studies, weaknesses in these studies can also be 
highlighted. Therefore, some have advocated that meta-analysis of clinical studies provides a sound 
basis for economic evaluation by giving a more precise and more representative estimate of treatment 
effect than a single clinical trial.(Simes and Glasziou, 1992; Mugford, 1989). CHE Discussion Paper 173  3
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Figure 1: The Relationship Between Meta-Analysis and Systematic Review 
 
In the next section, a checklist of the steps of meta-analysis is presented, first describing standard 
advice as recommended by methodologists, and second how this advice may differ in view of the 
needs of economic evaluation. 
 
3  STEPS IN THE CONDUCT OF META-ANALYSIS OF CLINICAL DATA FOR 
ECONOMIC EVALUATION 
 
The conduct of a meta-analysis of clinical data for economic evaluation should follow similar rules to 
that of evidence-based medicine to minimise potential biases or confounding as far as possible. 
Guidelines have been proposed for the undertaking of meta-analysis (e.g. Cochrane 
Collaboration,1996; Deeks et al, 1996), and there seems to be agreement and consensus on the basic 
principles. The standard format as followed by the Cochrane Collaboration, an international network 
aimed at preparing, maintaining and disseminating systematic reviews on the effects of health care, is 
shown in Box 2.  
 
Box 2: Standard Steps Involved in Conducting a Systematic Review 
1.      Development of a Protocol 
2.     Formulation of the Problem 
3.    Location and Selection of Studies 
4.     Critical Appraisal of Studies 
5.      Collection of data   
6.     Analysis and Presentation of Results 
7.    Interpretation of Results  
8.  Improving and updating Reviews 
       Cochrane  Collaboration,  1996 The Use of Meta-Analysis in Economic Evaluation  4 
3.1.  Development of a protocol 
 
It is generally recommended as with any scientific endeavour, that the methods of the meta-analysis 
should be established beforehand in the form of a protocol. This is to ensure a systematic and 
structured approach to the meta-analysis. It is desirable to make the process as rigorous and well 
defined as possible since reviews are essentially retrospective studies of data, and are vulnerable to 
many potential biases. The protocol will typically address the objectives, selection criteria, search 
strategy and methods, preceded with a brief summary of the biology, psychology/sociology and 
healthcare issues that provide the rationale for the review and place the questions in context. Although 
the motivations behind conducting meta-analyses are invariably different, the Cochrane Collaboration 
emphasises the main purpose of meta-analysis is to ‘provide unbiased, up-to-date summaries of what 
we know and do not know about the effects of different forms of healthcare and should help people 
make practical decisions about healthcare’.  
 
Similar conscientiousness applies to meta-analysis for the needs of economic evaluation. Methods of 
the meta-analysis should be established in advance in the form of a protocol, to ensure that the 
effectiveness data for the economic evaluation is derived in a systematic and unbiased manner, since 
selective use of effectiveness data can lead to erroneous  findings for the economic analysis. As 
Freemantle and Maynard (1994) pointed out in their example of SSRIs, if one of the smaller trials is 
selected rather than drawing upon all trials as a basis of calculating health gains, the cost-effectiveness 
of the intervention can be made to appear more attractive. 
 
Every effort should be made to adhere to the protocols, but it is appreciated that sometimes, this is not 
practically possible or appropriate as reviews are analyses of existing data which are constrained by 
previously-chosen study populations, settings, interventions, outcomes measures and study designs. 
Changes are only acceptable if they have not been performed post-hoc on the basis of results of the 
meta-analysis, and where changes are necessary, they should be documented and reported, and 
sensitivity analyses used to assess the impact of such decisions on the meta-analysis. However, in the 
case of  economic evaluations, changes to the type of economic study performed are probably quite 
likely. Prior to the conduct of the meta-analysis, it is unlikely to be able to specify whether an 
economic evaluation would be a cost-effectiveness or cost-minimisation study. Donaldson et al. 
(1996) argue that it is not necessary to know at the outset whether the experimental therapy is the 
same, better or worse than the control therapy in terms of effectiveness, otherwise if these answers 
were known, there would be little point for performing the experiment.    
 
3.2.  Formulation of problem 
 
It is generally recommended that the analyst should define and frame precisely in advance, the 
question(s) of the meta-analysis, since the overall framework is driven by the research question(s) and 
its associated hypothesises. The question(s) is also particularly important in that the readers of the 
meta-analysis can judge whether the meta-analysis is interesting or likely to be relevant to issues that 
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Questions that a meta-analysis may address can be broad or narrow in scope. A broad question might 
be; ‘Are antiplatelet agents effective in preventing thrombolytic events in humans?’ whereas a 
narrower question might be; ‘Is aspirin effective in decreasing the risks of a stroke in elderly patients 
with a previous history of stroke?’. The scope of the question is dependent upon multiple factors such 
as the question’s relevance and potential impact, availability of supporting information, the potential 
generalisability and validity of answers to the questions, the available resources, as well as the needs 
and requirements of the sponsor of the study.  
   
In terms of the needs of economic evaluation, the clinical research question of the meta-analysis 
should be broadly in line with the scope of the economic research question. Economic research 
questions can be broad or narrow. A meta-analysis designed to answer a broad research question such 
as ‘Are antihypertensive agents effective in lowering blood-pressure?’ is more suitable for a broad 
economic research question such as ‘Does the cost-effectiveness of treatment improve with increasing 
pre-treatment blood pressure ?’, rather than a narrower economic question such as ‘Is the cost-
effectiveness of β-blocker treatment for severe hypertension more cost-effective in the 50-70 age 
group ?’. There is a danger that clinical studies assessing broad questions can conceal different patient 
selections and give results that don’t relate to actual patients who have known attributes of risk; e.g. 
age 50-70 with severe hypertension, so there may be cases when generalisations are made, when they 
should not.   
 
In general, meta-analyses tend to be conducted to answer questions which are broad in nature. A 
background search of the clinical literature may be helpful in refining the questions of both the meta-
analysis and the economic evaluation.  
 
There are several advantages and disadvantages to framing broad or narrow questions. Narrowly 
focussed meta-analyses may not be generalisable to multiple settings, populations and formulations of 
an intervention or can lead to spurious conclusions. Alternatively broadly based reviews could be 
criticised for mixing apples and oranges, particularly when there is good evidence to suggest that 
various formulations of interventions behave very differently or that various definitions of the 
condition of interest or the setting are associated with markedly different courses and outcomes. On 
the practical side, searches for data relevant to broad questions may be more time-consuming and 
more expensive than narrowly defined questions, since broad questions may be addressed by large 
sets of heterogenous studies, and the synthesis and interpretation of data can be particularly 
challenging.  
 
There are several components to a well-formulated question.  A clearly defined question should 
specify the population, types of interventions or exposures, types of outcomes, and the types of 
studies that are relevant. The first component of the question is the population and setting for the 
disease or condition of interest. The population characteristics can be based on a series of factors such 
as age, sex, race, diagnosis, prognosis, educational status or presence of a particular condition such as 
angina or shortness of breath, whereas setting characteristics can be based on people living in the 
community, hospitalisation, living in nursing homes or chronic care institutions or outpatients. 
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The second key-component is to specify the interventions of interest and the control groups.  A threat 
to the validity of an economic evaluation is the choice of comparator intervention. In many clinical 
trials, placebo is selected as the comparator as it is normally a regulatory requirement for 
pharmaceuticals in many countries.  In economic studies, the comparator intervention should be most 
relevant for the policy question being addressed, and is typically usual practice. Comparators will tend 
to differ in different settings. Therefore there is potential for disparity to arise between the choice of 
comparator for the economic evaluation and the comparators in the clinical studies that are available 
for inclusion in the meta-analysis. Thus it is important to design the meta-analysis so that it includes 
clinical studies which contain relevant comparators and improve the external validity of the economic 
evaluations where possible.  
  
The third component is the delineation of particular outcomes of interest. Meta-analysis may be used 
to derive estimates of a main outcome or outcomes such as rare events. The selection of outcome 
measures for the meta-analysis is a difficult one as the range of outcome measures used in clinical 
studies is often diverse, and this is further complicated by the fact that they are measured very 
differently. Outcomes may be continuous such as blood pressure or weights; categorical such as 
mortality or pap smear classes; dichotomous such as  survival or death; and counts such as the number 
of live births or the number of myocardial infarctions.  
 
The summary outcome measure calculated in a meta-analysis is usually an odds ratio or risk ratio. The 
odds are defined as the number of patients who fulfil the criteria for a given endpoint compared to the 
number of patients who do not.  In any given study, there may be multiple outcome variables e.g. 
mortality, morbidity, and quality of life; and a given outcome variable may be expressed using more 
than one treatment effect measure. It is considered generally advisable to collect raw data on outcome 
measures e.g. numbers treated rather than derived measures such as odds ratios, since derived 
measures might not be of interest in the meta-analysis,  calculated incorrectly by the authors, or 
confusing when trying to compare the results of studies that are reported using different outcome 
measures. If truly disease outcomes are present measuring different constructs such as mortality and 
clinical improvemento, then no meta-analysis should be performed. If different measures or scales 
such as odds ratio or risk-difference using same construct are present, then meta-analysis could be 
performed by using the standardised effect size. Further, economic evaluations may involve decision-
analytic models which require an estimate of the conditional probability or absolute risk (rather than 
the relative risk). These absolute risks can be calculated directly from primary studies using common 
statistical methodology to combine proportions for both intervention and control groups (Laird et al., 
1990).  
 
Exclusivity can introduce the threat of bias in the reporting of outcomes. The choice of outcome(s) in 
clinical studies which are reported and the measurement tools which have been used to measure these 
outcomes, can be influenced by ex-post viewing of the results and occasionally, can be the ones with 
the most favourable findings.  An example is the dichotomisation of continuous variables in 
pharmaceutical clinical trials. This is potentially problematic as meta-analysis can only summarise 
outcomes which are contained in the original studies in the first place. As the choice of outcomes can 
make a crucial difference to the conclusions of the meta-analysis, they should be selected with care. In CHE Discussion Paper 173  7
some instances, however, the outcomes for economic evaluation maybe different to those offered in 
the meta-analysis. Therefore it might be advisable to approach authors or sponsors for unpublished 
data. 
 
Clinical studies may contain health-related quality of life scales. The different types of scales have 
been reviewed by Guyatt et al (1993) and can be classified into (i) specific measures; (ii) general 
health profiles; and (iii) preference-based measures. With respect to economic evaluation, preference-
based measures can be relatively easily incorporated, but specific measures and general health profiles 
are not as straightforward, requiring complex mapping of health states to established preference-
weighted classification or alternatively using the quality of life information from the scales to 
construct scenarios for health state preference evaluation. Economists should be aware of these 
limitations, when looking to meta-analyse data on quality of life.  
 
The final key component is the types of study designs. Certain study designs are superior to others 
when answering particular questions. A hierarchy of study designs has been proposed for clinical 
epidemiological studies (Sackett et al. 1995), which range from large, well controlled, randomised 
controlled, double-blind trials to small, non-randomised studies.  With differing degrees of bias 
inherent in each study design,  Cook et al. (1992) have correspondingly proposed levels of evidence 
and grades of recommendation. Randomised controlled trials (RCT) are regarded in clinical circles as 
the gold standard research design, followed by cohort studies, case-control studies and case 
series. Indeed, the Cochrane Collaboration focuses on systematic reviews of RCTs for this reason. In 
comparisons of therapies, differences in outcome may be as a result of biases, confounding or chance 
rather than due to the differences between therapies under evaluation. The framework of a randomised 
controlled trial minimises the possibility of selection bias arising through the selection of patients for 
each treatment, and therefore it is not unexpected that the majority of meta-analyses performed 
include only randomised controlled trials. When multiple randomised controlled trials are brought  
together in a meta-analysis, the randomisation is preserved and hence provides a more precise 
estimate of treatment effect. It is particularly important to analyse the trials in terms of treatment 
allocated (intention-to-treat analysis).  
 
Box 3: The Relationshipt Between Levels of Evidence and Grades of Recommendation 
Level of Evidence       Grade  of  Recommendation 
Level 1,   Large RCTs with clear cut results (low risk of error)      Grade A 
Level 2,   Small RCTs with uncertain results (moderate to high risk of error)  Grade B 
Level 3,   Non-randomised, contemporaneous controls        Grade C 
Level 4,   Non-randomised, historical controls          Grade D 
Level 5,   No controls, case series only            Grade E 
          Cook  et  al.,  1992 
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Economists generally support the quality criteria established by epidemiologists, but in terms of 
economic evaluation there arises a conflict of quality of clinical evidence with the degree of 
relevance. Although the randomised controlled trial is a valid vehicle for assessing outcomes, the 
conditions under which trials are conducted are often atypical. For example; the case-load may be 
highly selective, the patient and doctor may be blind to the treatment assignment, the comparator may 
be placebo rather than usual practice, the trial protocol may demand additional tests or procedures to 
be performed, patients may be more closely monitored than usual at specialist centres and the 
physicians and patients may be more highly motivated than usual (Drummond and Stoddart, 1984; 
Drummond and Davies, 1991; Adams et al., 1992).  Furthermore, RCTs and even meta-analyses may 
be inadequate to detect certain clinical endpoints that are relevant to an economic evaluation. For 
example, if the economic evaluation of an intervention is based on the detection of adverse events that 
occur very rarely,  the randomised studies may offer very imprecise information because of their short 
follow-up and small sample sizes. In such circumstances economic evaluation using evidence from 
case-control or cohort studies where very small risk differences can be detected, may be more 
appropriate. For example, in their economic evaluation of SSRIs versus older tricyclics, Freemantle et 
al. (1994) used government databases to estimate the costs, volume of prescribing and number of 
deaths. In general, RCTs will invariably assess efficacy rather than effectiveness, under real-world 
conditions. Ideally economic evaluations should incorporate clinical data on effectiveness rather than 
efficacy, but these may not be available especially in the case of pharmaceutical research where the 
majority are Phase I to III studies geared towards establishing efficacy and safety for licensing 
purposes.  
 
Although combining data from studies using different designs may seem undesirable to 
epidemiologists for efficacy evaluation, this practice may be advantageous to maximise external 
validity, increasing relevance to policy and clinical practice decisions. For these reasons, in fact, 
economists may be satisfied to use data from the meta-analysis of non-RCT data, or in situations 
where no RCT data are available.  
 
Under development is a new form of meta-analysis called cross-design synthesis which uses 
complementary study designs such as randomised controlled trials and observational studies, based on 
the underlying principle of compensating for each others inherent design weaknesses to better answer 
study questions (Droitcour et al., 1993). For these reasons, cross-design synthesis may have potential 
use for economic evaluation in the future. 
 
3.3.  Location and selection of studies 
 
It is generally recommended that the search strategy to locate relevant studies as defined by the 
research question, should be as comprehensive as possible. This is a most critical and difficult step as 
publication bias is a major threat to the validity of a meta-analysis (Begg and Berlin,, 1989). 
Publication bias arises from the fact that clinically and statistically significant results are more likely 
to be published or presented at scientific meetings than negative ones. Thus it is possible that the 
subset of studies included in the meta-analysis could be unrepresentative.  CHE Discussion Paper 173  9
Publication bias can be prevented by prospectively registering clinical trials at their inception but 
universal registration of all studies cannot be realised in the near future. Therefore, every effort should 
be made to obtain and include data from unpublished studies. The publication bias in a meta-analysis 
could be assessed according to identified risk factors of publication bias such as small sample size, 
poor study design, small or moderate effect size, and the interest of research sponsors (Song et al., 
1999). The file-drawer method (Rosenthal., 1979) and funnel plot related methods (Egger et al., 1997) 
are often used in meta-analysis to detect the risk of publication bias.  
 
The comprehensive of the search will invariably be dependent upon the field and the research 
question that the meta-analysis is designed to answer. While computerised databases such as 
MEDLINE (Index Medicus online), EMBASE (Excerpta Medica Online), CINAHL and 
SCISEARCH (the Science Citation Index) may facilitate retrieval of relevant published studies, these 
searches are often insufficient. Dickersin et al. (1994) found that only 30-80% of all known published 
randomised trials are identifiable using MEDLINE and non-English language references are seriously 
underrepresented. Standard advice recommends that the computerised databases should be used as an 
initial step and supplemented wih searches of review articles, abstracts, conference/symposia 
proceedings, dissertations, books, expert opinions, trial registries, communication with industry and 
manual searches of relevant journals. Since the comprehensiveness and efficiencies of the database 
searches depends upon the keywords chosen, it is advisable for the economist to enlist the help from 
information scientists when designing a search strategy. In some cases, a systematic review might 
already exist in the area of interest. Before proceeding with a meta-analysis, the economist would be 
wise to check databases such as the Cochrane Database of Systematic Reviews, the Database of 
Abstracts of Reviews of Effectiveness (DARE), the National Research Register (NRR) and 
MEDLINE to avoid duplication of effort. 
 
It is within the best interests of the economist that careful consideration should be given to this stage 
to avoid erroneous conclusions, as in essence the results of the economic evaluation will be driven by 
the overview of the effectiveness data from the retrieved published and unpublished studies. An 
example of selection bias is a meta-analysis of paroxetine in the treatment of depression (Dunbar et 
al., 1991). In their study, a meta-analysis of six trials showed that there was a 12% reduction in risk in 
tolerability for paroxetine as compared to imipramine. However, a meta-analysis of all available 
studies suggested a more modest effect (Song et al., 1993).      
 
Despite the above, meta-analyses for economic evaluation may omit clinical studies on the basis of 
relevance to the economic research question. For example O’Brien et al. (1994) omitted two clinical 
studies on the basis that they contained drugs, not being assessed in the economic evaluation on 
prophylatic treatments against deep vein thrombosis (DVT). Similarly, Drummond et al. (1994) 
omitted a study on the basis that it contained a different dosing regimen to other heparin studies. Such 
omissions should be explored by sensitivity analysis.  
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3.4.  Critical appraisal of studies 
 
It is generally recommended that studies should be critically appraised prior to inclusion in the meta-
analysis, in order to understand the overall quality of the studies being combined, to detect the risk of 
bias, gain insight into potential comparisons and guide the interpretation of findings. Also criticial 
appraisal may pull out duplicate and sub-set publications. Furthermore one might wish to use a 
measure of study quality as part of the weight assigned to each study in the analysis or as a method to 
exclude poor quality studies. Moher et al. (1995) define quality as ‘the confidence that the trial 
design, conduct and analyses have minimised or avoided biases in the treatment comparisons’, 
implying that the likelihood that the results are closer to the ‘truth’ will be greater if the quality of the 
studies is higher.  
 
Typically the quality of the study is assessed, using quality scales or checklists (Moher et al., 1995). 
Several such checklists and scales are available including the Department of Clinical Epidemiology 
and Biostatistics, McMaster University User Guides to the Medical Literature (1981). However these 
methods will inevitably be subjective to some extent, and care should be taken not to confuse the 
quality of reporting with the validity of the design and conduct of a trial. Also the relative importance 
of characteristics of the studies which will be assessed for quality may be different for different 
research topics. 
 
3.5.  Collection of data 
 
It is generally recommended that data from primary studies are collected through the use of data 
extraction sheets. Data extraction sheets serve three functions; (i) as a visual representation of the 
review question and the critical appraisal of included studies in the meta-analysis; (ii) as a historical 
record of the decisions that occur throughout the review process and (iii) as a data repository form. 
Data extraction sheets will vary for the different reviews, but should be of suitable length to avoid 
omitting key data or becoming conversely tedious, boring and wasteful of time. Data extraction sheets 
can be electronic or paper form, the former having the advantage of being able to handle large 
amounts of data and eliminating the need for data entry separate from the abstraction. Typical data 
extracted may include items such as study design, setting, participants, interventions, outcome 
measures and results.  
 
It has been suggested that studies should be read independently by two readers to minimise inter-
reader variability (Begg, 1989), and hence improve reliability. Since by virtue, meta-analysis is being 
conducted after the data are available, meta-analysis is a form of retrospective research and is prone to 
potential biases inherent in such research. It is also advised that certain information such as the 
identity of the authors, the institutions at which the study was conducted and the sponsors of the study 
should be masked. Although this is ideal, however it is appreciated that this may be rather difficult to 
completely uphold in practice as it is difficult to attempt a review in a field without prior specialist 
knowledge of the field. CHE Discussion Paper 173  11
3.6.  Analysis and presentation of results 
 
Although statistical methods can be helpful to analyse and summarise data, it should not necessarily 
be regarded that a systematic review with no statistical analysis is less valuable. Statistical analysis 
can be more of a hindrance than a help to those who are not familiar with the statistical techniques, 
and statistical analysis may not be appropriate in certain cases where there is a lack of relevant valid 
data or where it does not make sense. For example; a summary of studies to improve prescribing 
could be very helpful to many different end-users, but a statistic of an average effect of interventions 
to improve prescribing could be meaningless and misleading.  
 
When it is possible and appropriate, statistical methods can be very helpful to summarise research 
evidence. The different statistical approaches to meta-analysis share a common goal, which is to 
provide a more precise and generalisable estimate of treatment effect than that attainable from any 
individual study. The overall effect is estimated by weighting each individual effect inversely 
according to its variance. There are two general methods available to produce a combined estimate of 
effect size; one is based on the fixed effects model and the other is on the random effects model. 
These two methods are different in their assumptions about the true underlying effect size of each 
study (Sutton et al., 1998).  
 
Heterogeneity of the results from different studies can be assessed through the use of statistical tests, 
but these tend to be of low power. Therefore the failure to reject the hypothesis of homogeneity of 
studies does not prove that the studies are estimating the same effects size. Actually, any set of studies 
is inevitably heterogeneous and there are many possible sources which might cause a failure of the 
assumptions by the fixed effects model. A remedy is the use of graphical displays to search for 
variable treatment effects. If heterogeneity of treatment effect is demonstrated, then the possible 
underlying sources of heterogeneity should be investigated and subgroup analysis applied. 
 
The fixed effects (FE) model assumes that all the studies have identical underlying effect sizes, and 
different results across studies are purely due to random error. This implies that if all the studies were 
infinitely large, they would generate identical results. Under this assumption, the variance of the 
estimated summary effect size is exclusively determined by the within-study variance of each 
component study. The random effects (RE) model assumes that studies have different underlying 
effects that are normally distributed. This implies that even if all the studies were infinitely large, they 
would generate different results. Under this model, between-study variance needs to be taken into 
account as well as within-study variance in deriving the weighting factor (DerSimonian and Laird, 
1986).  
 
Economists should be careful in selecting the relevant model as occasionally, both types can generate 
conflicting conclusions from the same data. The random effects model will be more ‘conservative’ 
(Pettiti, 1994) because it provides a wider confidence interval of estimated overall effect. As the 
between study variance or heterogeneity becomes large, the difference in results of the two models 
will increase. In this situation, the random effects model will take into account the heterogeneity, 
which the fixed effects model tends to ignore. The Use of Meta-Analysis in Economic Evaluation  12 
Sources of heterogeneity could be investigated by subgroup analysis and meta-regression. The 
treatment benefit is often greater for those most at risk. For example, the segments of population with 
the higher levels of hypertension, may benefit most from antihypertensive drugs and in programmes 
of immunisation and screening, the segments of the population where the incidence is high may 
benefit. Inevitably the cost-effectiveness will vary according to different patient characteristics.  
 
The robustness of a meta-analysis can be investigated through sensitivity analysis. Particularly if 
clinical data used in meta-analysis is limited or not reliable, the economist can undertake a sensitivity 
analysis based on different assumptions about the clinical evidence. For example, the long-term 
outcome is often not available because of inadequate follow-up as frequently witnessed in clinical 
trials. Alternatively the estimates from a meta-analysis may be included as part of a sensitivity 
analysis for testing the robustness of the estimates of the clinical data on which the economic 
evaluation is based. That is, if the economic evaluation is based on a single prospective study, a meta-
analysis of the previously published literature could provide estimates for the sensitivity analysis.  
 
There are several reasons why explicit reporting of the meta-analysis contained in the economic 
evaluation is desirable. First, it improves the transparency of the economic evaluation and makes it 
easier to assess whether the methods were appropriate. Secondly it facilitates comparisons between 
studies; that is the differences in cost-effectiveness ratios for example is due possibly to differences in 
study methodology rather than in the effectiveness. Thirdly, it might act as a stimulus to improve the 
quality of the meta-analyses undertaken. As with any research, the economic evaluation and the meta-
analysis should provide sufficient information for replication of the methodology. 
 
3.7.  Interpretation of results 
 
The strength of evidence and the extent of the applicability of results should be discussed to aid 
decision-makers in interpreting the results. The strength of evidence might involve a consideration of 
the methodological limitations of the included studies in the meta-analysis and the methods used that 
might affect practical decisions about healthcare or future research. The extent of applicability of the 
results is very important because the circumstances of the studies included in the meta-analysis are not 
necessarily the same as others. Discussion should focus on the spectrum of circumstances to which the 
evidence is likely to be applicable or not applicable and predictable variation in effects across 
different circumstances.  Examples include biological and cultural variation, variation in compliance 
and variation in baseline risk.  
 
The issue whether to adjust the clinical results from the meta-analysis is a complicated one. For 
example, should adjustments be made for the likelihood of lower compliance in actual clinical use? 
Poor compliance reduces the apparent effectiveness, but also the costs. Alternatively should 
adjustments be made for the possibility that the trial protocol affect cost or benefits?  (e.g. less 
depressed people are less likely to comply with a/d therapy and are most likely to spontaneously 
recover and how would average effectiveness change in a different compliance pool). CHE Discussion Paper 173  13
O’Brien et al. (1995) wanted to assess the cost-effectiveness of H. Pylori eradication relative to 
alternative pharmacologic strategies in the long-term management of persons with confirmed 
duodenal ulcer (D.U.). A key factor was the probability of ulcer recurrence (at six months and 12 
months) under the various regimens. Given the large number of randomised trials, they performed a 
meta-analysis to estimate the probabilities. However, in the ulcer trials, the rates of recurrence are 
estimated by endoscopic examination. This is problematic as economic evaluation seeks to estimate 
costs and consequences as they would occur in normal clinical practice, in which patients would not 
be endoscoped unless they had bothersome symptoms and consulted their physicians. Therefore it is 
likely that some of the ulcers detected by endoscopy would be asymptomatic or silent. In order to 
account for this O’Brien et al.(1995) reviewed the trials that reported symptomatic and asymptomatic 
recurrence separately and estimated that about 75% of recurrences determined by endoscopy are 
symptomatic (See box 4). The adjusted rates of ulcer recurrence were used in their cost-effectiveness 
model. The issue is whether effectiveness estimates of each study to be included in the meta-analysis 
should be adjusted a priori with the meta-analysis, or ex ante. 
 
Box 4: Adjustment to Trial-Based Data in a Study of Ulcer Therapy 
                   Ulcer Recurrences Per 1000 Patients  
              E x p e c t e d   o n e - y e a r  
Strategy         Total              Symptomatic       cost per patient 
 
1. Heal and wait; 
    treat DU recurrence with: 
    (a) ranitidine     108 (100%)     81 (75%)      329 
    (b) Omeprazole    108 (100%)     81 (75%)      341 
 
2. Heal and H. Pylori 
    eradication immediately with: 
    (a) omeprazole and  
         amoxicillin      20 (100%)    15 (75%)      272 
    (b) triple therapy    20 (100%)    15 (75%)      253 
 
       Adapted  from  O’Brien  et  al.  (1995) 
 
3.8.  Improving and updating reviews 
 
Cumulative meta-analysis entails repeating at periodic intervals, the steps in the original meta-
analysis. From a technical viewpoint, the establishment of databases to allow the prompt updating of 
meta-analyses presents many opportunities. As these databases become more developed, it will 
become easier for economists to update the clinical evidence on which their economic evaluations are 
based. Clinical practice is subject to rapid change, but equally policy makers need to make the best 
decisions they can today, recognising that the data is not (may never) be perfect. The importance of 
updating a meta-analysis is also highlighted by the fact that studies with positive or significant results 
are often published ealier than those with negative or non-significant results (Song et al., 1999). The 
treatment effect may therefore be overestimated if studies that become available sebsequently are not 
included. The Use of Meta-Analysis in Economic Evaluation  14 
4.  ISSUES SURROUNDING THE META-ANALYSIS OF ECONOMIC EVALUATIONS 
 
Intuitively, health economists have a number of reservations towards combining economic data. 
Firstly, there has been substantial discussion on the reliability of cost-effectiveness ‘league tables’ and 
the degree of comparability between individual economic studies owing to different technical 
specifications (Mason et al. 1994). It is also not immediately evident which technical components of 
economic evaluation can be summarised. Secondly, doubts have been expressed on the transferability 
of economic data from setting to setting as resource usage or costs may be specific to countries or 
regions (Drummond et al. 1992). 
 
Despite these concerns, there are several reasons why health economists might be interested in 
conducting a meta-analysis of existing economic evaluations. In practical terms, performing a meta-
analysis could be potentially less costly and less time-consuming than performing further primary 
economic studies (Mulrow 1995) though this merits further investigation. For example, the alternative 
to a meta-analysis might be to conduct a much larger economic study than those already in existence. 
Universally, but especially apparent in developing countries, there are healthcare providers, 
researchers and policy makers with access to severely limited financial resources for obtaining 
research-based information.  
 
Also, there are situations when decisions need to be made based on limited information. Meta-analysis 
may give decision-makers confidence that they are making the best use of what economic evidence is 
available at the time. The use of meta-analysis in the reimbursement approval process of drugs 
represents a potential application. Currently two jursidictions, the Commonwealth of Australia and the 
Province of Ontario, Canada have cost-effectiveness as a criterion in order to secure reimbursement. 
Currently assessments are based on one or more primary economic evaluations. However, as more 
studies are published, meta-analysis could potentially assist the reimbursement authorities in their 
decisions through summarising the best available economic evidence at the time alongside the clinical 
evidence.  
 
From a technical point of view, meta-analysis may provide a solution to the issue of generalisability. 
Economic evaluations have often been critiqued as being specifically restricted to particular contexts 
or settings. Furthermore, a structured assembly of results from previous studies allows for the 
exploration of reasons for inconsistencies and variability. Finally, meta-analysis may provide a 
stimulus for updating knowledge in a particular disease area and providing guidance concerning the 
design of future economic studies. 
 
5.  REVIEW OF ECONOMIC EVALUATIONS CONTAINING META-ANALYSES 
 
To date, relatively few economic studies have employed data from meta-analysis as a source of 
estimates of treatment effectiveness. Mugford et al. (1989) conducted a cost-effectiveness study of 
antibiotic prophylaxsis in caesarian section, based on data from a meta-analysis of 58 controlled trials, 
which estimated that the odds of wound infection reduced by 50-70%. Mugford et al. (1991) also 
employed a meta-analysis of trials to estimate the effects of corticosteroids and surfactants for CHE Discussion Paper 173  15
reducing respiratory distress syndrome and death before discharge. In their comparison of anti-fungal 
agents in terms of cost-effectiveness for the treatment of onychomycosis of fingernails and toenails in 
13 countries, Arikian et al. (1994) conducted a worldwide meta-analysis of randomised controlled 
trials to derive clinical success rates, relapse rates and side-effect rates. Similarly meta-analysis has 
been applied to estimate outcome probabilities in decision analytical models. Einarson et al. (1995)  
employed a meta-analysis of 34 studies to derive success rates, relapse rates and adverse events for 
their decision analysis model in the examination of oral antidepressants in the management of major 
depressive disorders. Jefferson and Demichelli (1994) have undertaken a meta-analysis of both the 
epidemiological and economic variables pertaining to vaccination against hepatitis B. The meta-
analysis of economic data is, however, at an early stage of development.   
 
The conduct of meta-analyses for the purposes of economic evaluation has been far from adequate. In 
a search of the NHS Economic Evaluation Database, 28 economic evaluations (see table 1) were 
retrieved  which had derived their measure of effectiveness based on a meta-analysis of clinical 
studies. Yet in many cases the authors failed to satisfy some of the requirements for a sound meta-
analysis (box 5). 
 
Box 5: Limitations of Meta-Analyses of Clinical Data in 28 Economic Evaluations 
Limitation        Number  of  studies 
Failure to state source of studies           15    
Small number of studies or number of studies not stated      10   
Mixing of experimental and observational study designs     12   
No quality assessment of studies          22   
No  weighting  of  studies        20   




Meta-analysis provides a family of statistical techniques for combining the results of similar studies.  
It is a useful tool for economists to explore estimates of effectiveness of interventions. This paper has 
attempted to highlight the issues and considerations that must be addressed when designing and 
conducting a meta-analysis of clinical data for use in an economic evaluation.  
 
To address a specific resource question, an economic evaluation should be based on reliable 
information about the relative effect of treatments that are compared. For the purpose of economic 
evaluation, a meta-analysis of clinical data should address a specific clinical question, determine 
which studies and data are valid, and how they are synthesised. It is appreciated that meta-analyses are 
retrospective in that they are potentially subject to many of the same biases which affect other 
retrospective studies. Therefore a meta-analysis is reliant upon good clinical study methodology as 
well as good review methodology.  The Use of Meta-Analysis in Economic Evaluation  16 
Although more and more economic evaluations are being performed alongside clinical trials, it is 
unlikely that economists will ever dispense with modelling. In fact, modelling is ‘an unavoidable fact 
of life’ and the need for the meta-analysis of clinical data will remain with us for many years to come. 
Obviously there still exists much potential for development. Performing economic evaluations based 
on effectiveness data from meta-analysis makes a lot of sense because meta-analysis can provide 
reasonable effectiveness estimates for economic evaluations when no large trial has been performed.  
 
The next step? In the summing up of the Potsdam Consultation on meta-analysis in March 1994, Cook 
et al. recommended that economists and epidemiologists should collaborate to determine how to 
incorporate economic evaluation into systematic reviews.  However before this next step can be a 
possiblity, economists should seek to strengthen the methodology of economic evaluation as far as 
possible, and one of these facets is to improve the quality of clinical effectiveness data on which 
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Table 1 Studies Containing ‘Meta-Analyses’ From the NHS Economic Evaluation Database  
 Authors  Health care 
intervention 
Outcomes  Method of combination  Results 



























No  Reduction of low birthweight 
babies by 3.01% 
Reduction of very low 
birthweight babies by 
1.13% 
2 Blaufox  MD 
















Yes  e.g. Diagnostic test captopril 
renogram 
sensitivity = 89% 
specificity = 92% 
positive predictive value = 83%  
3 Chancellor  JV 







Risk of disease 
progression, risk 
of AIDs and risk 
of death 
Not stated  6  RCTs  No  No  No  Relative risk = 0.509 




















MEDLINE 25  Not 
stated 
Yes No No  Not  stated 
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Table 1 cont’d 
5 Cummings  SR 
et al. 1989 
Physician 
advice to stop 
smoking 
Quit rate of 1 year  MEDLINE 
+review 
bibliographies 
7  RCTs  No  No  No  Quit rate at 1 year = 2.7% 









153 RCTs  Yes  Yes 
(inverse of 
variance) 
No  Change in DBP = -9.8 (propranolol 
hydrochloride), -7.4% 
(hydrochlorothiazide), -10.0 
(nifedipine), -8.1% (prazosin 
hydrochloride), -4.9 (captopril) 
7 Einarson  TR 





relapse rates and 
adverse events 




(TCA), 49.2% (HCA) 
30.3% (SSRI) 
 


















No No No  Probability  of  endoscopically 
proven ulcer = 0.216, effectiveness 
= 0.74, 
relative risk = 3.0, 
proportion aged 60+ = 0.5 
















4  RCT  No No No  Caesarian  rate  =  24.5% 











18 RCT  Yes  Yes 
(quality) 
No  Risk of iatrogenic 
complication=6.7% (TPN) 
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Table 1 cont’d 









21  RCT  Yes  No  No  Mortality = 23.7% (1st yr), 20.4% 
(2nd year), 30.9% (3rd year) 






CHD and stroke 
Not stated  Not stated  Not 
stated 
No  No  No  Reduction in CHD = 16%, 
reduction in stroke = 38%  





CHD and stroke 
Not stated  Not stated  Not 
stated 
No  No  No  Reduction in CHD = 38%, 
reduction in stroke = 16% 














17  RCT  No  Yes  Yes  Mean decrease in DBP =5-6mmHg; 
CHD risk reduction=16%, stroke 
risk reduction=40% 





CHD and stroke 
Not stated  Not stated  Not 
stated 
No  No  No  Reduction in CHD = 38%, 
reduction in stroke = 16% 














No No  Yes 
(random 
effects) 
Mycologic cure rate=41%(GRI), 
79%(ITR), 16%(KET), 87% (TER).  













Not stated  8  RCT  No  No  No  Reduction in myocardial infarction 
= 9%, reduction in stoke = 40% 














Yes  Time without depression = 8.2 
months (standard therapy), 7.6 
months (citalopram) 
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Table 1 cont’d 
19  O’Brien B et 
al. 1994 
Prevention of DVT 





Not stated  10  RCT 
 
No  No  Yes  Risk differenceo f DVT = -7.1 
(overall,  -8.2 (distal) 
20  O’Brien B et 
al. 1995 







MEDLINE 12  RCT  No  Yes 
(inverse of 
variance) 
No  Pooled rate of recurence = 65.4% 
(placebo), 12.8% (rantidine) 
21  Oster et al. 
1986 
Nicotine gum to 
facilitate smoking 
cessation 
1 year cessation 
rate 
Not stated  Not 
stated 
RCT  No  No  No  Cessation rate = 4/5% (advice & 
counselling), 35% (gum) 








for the prevention 
of DVT after 
surgery 




Not stated  Not 
stated 
RCT  No  No  No  Signifiant difference in clinical 
outcomes for stockings vs 
prophylaxis 
23 Sintonen  H, 
Alander V. 
1990 
Omeprazole   Healthy days  Not stated  Not 
stated 
RCT No  No  No  Healthy  days=  121.5(Omeprazole), 
88.2  (ranitidine), 89.6 (Sucralfate)  
24 Sonnenberg  A 
et al. 1995 
Duodenal ulcer 











No  No   No  Healing rate = 77%(H2 anaag 
onists), 95% (anti 
secretory+antibiotics); recurrence 
rate=2.5% (H2 antagonists), 25% 
(vagotomy) 
   25
Table 1 cont’d 














No  No No Symptom  relief=0.68  (antacids),  0.63 
(placebo), 0.75(H2RA), 0.80 (PPI) 
26  Van den Boom 
et al. 1996 
Omeprazole and 
reflux surgery 










No Effectiveness  (healing stage) = 91% 
(omprezole 40mg); = 88% (maintenance 
stage) 








risk of death 
Not  stated  15  RCT  No  No No Healing rate=93% (omeprazole); 83& 
(ranitidine); relapse risk=6.5% (without 
txt), =2.0% (with txt). Risk of 
death=20% 
28  Wong et al. 
1995 
Treatment of 







HBsAg and the 
relative risk for 
developing 
cirrhosis 
MEDLINE  9  RCT  No  No  Yes  Pooled odds for interferon-alpha-2b for 
HBeAg disappearance =7.4%. Relative 
risk for developing cirrhosis=2.39 
 
 